肝癌经皮门静脉时辰化疗生存期的初步观察

Preliminary survival observation on purcutaneous portal vein chronomodulated chemotherapy on treatment of liver cancer.

探讨不能手术切除的中晚期肝癌的治疗新途径,延长其生存期。对21例肝癌患者在TACE治疗后再经皮穿刺门静脉置管,采用微电脑控制的全自动注药盒每天在特定的时间向门静脉内注入顺铂(DDP)及5-氟尿嘧啶(5-Fu)进行时辰化疗并与对照组进行比较。结果表明:治疗组1年生存率41．69％,2年生存率27．79％,中位生存时间12．40月;对照组1年生存率23．33％,2年生存率10．00％,中位生存时间8．67月;经统计学分析,有显著性差异。提示门静脉置管时辰化疗联合TACE治疗中晚期肝癌疗效较为满意,值得进一步探索和研究。

To explore the new therapeutics on patients with unable surgical excisional advanced liver cancer, so elongating the survival. After TACE treatment, 21 patients with advanced liver cancer were treated by means of the portal vein chronomodulated chemotherapy by which DDP and 5 - Fu was infused into the portal vein through the catheter had inserted in it. Treatment group： the 1 year survival is 41.69%, the 2 year survival is 27.79%, the medial survival is 12. 40 months. Compared with the controlled group, the survival is more longer significantly. It is demonstrated that portal vein chronomodulated chemotherapy combined with TACE on treatment of liver cancer is an effective therapy, It is worth to explore and study more.